The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
Texas MPN Workshop 2022 | The importance of genomic testing in MPNs and other myeloid malignancies
Rafael Bejar, MD, PhD, University of California San Diego, San Diego, CA, shares some insights into the importance of genomic testing in myeloproliferative neoplasms (MPNs) and other myeloid malignancies, and further discusses the value of testing patients for clonal hematopoiesis of indeterminate potential (CHIP). This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.
Disclosures
Aptose Biosciences – employment and equity
Gilead – data safety monitoring committees chair
Epizyme – data safety monitoring committee chair
BMS – ad hoc advisory board honoraria, research funding
Takeda – research funding
